Results 61 to 70 of about 16,304 (256)
Proceedings of the National Academy of Sciences, 2015 The development of biosimilars should have a big impact on patients, insurers, and pharmaceutical companies for years to come. Image courtesy of Shutterstock/Sasa Komlen.
openaire +3 more sources
Biosimilars – terms of use [PDF]
Current Medical Research and Opinion, 2015 The impending expiry of the patent on a number of leading biologic drugs has led to a surge in the development of 'biosimilar' or 'follow-on' products. However, in contrast to generic small-molecule medicines, biosimilars are not identical to their reference products.
Declerck P, Mellstedt H, Danese S
openaire +4 more sources
The Inflation Reduction Act and Etanercept
Arthritis &Rheumatology, EarlyView.
Charles L. Bennett +6 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Optimal dosing of oncological drugs is historically determined based on the “higher is better” paradigm. However, a paradigm shift in optimal dose selection has occurred in the development of new modalities, including molecularly targeted drugs, antibody drugs, and immunotherapies.
Hiroe Kitagaki +3 more
wiley +1 more source
The Journal of Clinical Pharmacology, EarlyView.Abstract This study utilized model‐based meta‐analysis (MBMA) to systematically assess the efficacy of methotrexate (MTX) monotherapy in improving rheumatoid arthritis (RA) symptoms and function. The assessment was based on indicators such as Disease Activity Score 28 (DAS28), Health Assessment Questionnaire, and American College of Rheumatology (ACR ...
Shengyang Chen +5 more
wiley +1 more source
Biosimilars, 2011 Bhupinder Singh Sekhon, Vikrant SalujaInstitute of Pharmacy, PCTE Group of Institutes, Near Baddowal Cantt. (Ludhiana), IndiaAbstract: “Biologics”, considered one of the fastest growing sectors of the pharmaceutical industry, has introduced many new treatments to life-threatening and rare illnesses.
Vikrant Saluja, Bhupinder Singh Sekhon
openaire +4 more sources
Journal of Chemical Technology &Biotechnology, EarlyView.Abstract BACKGROUND In recent years, biopharmaceutical applications in medicine have seen explosive growth and the need for efficient, rapid and inexpensive purification of these targets is the topic of tremendous research and development. The need to improve process efficiency has been an active area of investigation due to the tremendous potential ...
Yasmina MJ Harsy +5 more
wiley +1 more source
Biosimilars in rheumatology: what the clinician should know
RMD Open, 2015 Biosimilars are now a reality in rheumatology. Although analytical and non-clinical procedures to establish similarity have evolved significantly, clinical trials demonstrating equivalent efficacy and safety are absolutely required for all biosimilars ...
Jonathan Kay +3 more
doaj +1 more source
The Future of Biosimilar Insulins [PDF]
Diabetes Spectrum, 2016 IN BRIEF Biosimilar insulins are available in many countries and will be made available in the United States in the near future. Some concerns associated with biosimilar insulins include potential differences in the efficacy and safety between a biosimilar product and its reference insulin, the ramifications of having the same name or different names ...
Kim, Anne Park, Bindler, Ross Jason
openaire +3 more sources
Recent Advancements in the Treatment of Age‐Related Macular Degeneration
Med Research, EarlyView.ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu +10 more
wiley +1 more source